By: Benzinga
UPDATE: Oppenheimer Initiates Cleveland BioLabs at Outperform; A Unique Opportunity
Oppenheimer initiated coverage on Cleveland BioLabs (NASDAQ: CBLI ) with an Outperform rating and a $3 price target. Oppenheimer commented, "Biodefense drug development has a unique risk/reward risk profile. On the positive side, there is nondilutive capital from the government to cover R&D, no need for marketing/salesforce since government
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here